JP2025016684A5 - - Google Patents

Info

Publication number
JP2025016684A5
JP2025016684A5 JP2024193094A JP2024193094A JP2025016684A5 JP 2025016684 A5 JP2025016684 A5 JP 2025016684A5 JP 2024193094 A JP2024193094 A JP 2024193094A JP 2024193094 A JP2024193094 A JP 2024193094A JP 2025016684 A5 JP2025016684 A5 JP 2025016684A5
Authority
JP
Japan
Prior art keywords
thiadiazol
difluoromethyl
indazol
amino
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024193094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025016684A (ja
JP7781244B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2020/051486 external-priority patent/WO2021055744A1/en
Application filed filed Critical
Publication of JP2025016684A publication Critical patent/JP2025016684A/ja
Publication of JP2025016684A5 publication Critical patent/JP2025016684A5/ja
Application granted granted Critical
Publication of JP7781244B2 publication Critical patent/JP7781244B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024193094A 2019-09-20 2024-11-01 Parg阻害剤としての4-置換インドールおよびインダゾールスルホンアミド誘導体 Active JP7781244B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962903438P 2019-09-20 2019-09-20
US62/903,438 2019-09-20
PCT/US2020/051486 WO2021055744A1 (en) 2019-09-20 2020-09-18 4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
JP2022517374A JP2022548690A (ja) 2019-09-20 2020-09-18 Parg阻害剤としての4-置換インドールおよびインダゾールスルホンアミド誘導体

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022517374A Division JP2022548690A (ja) 2019-09-20 2020-09-18 Parg阻害剤としての4-置換インドールおよびインダゾールスルホンアミド誘導体

Publications (3)

Publication Number Publication Date
JP2025016684A JP2025016684A (ja) 2025-02-04
JP2025016684A5 true JP2025016684A5 (enExample) 2025-09-08
JP7781244B2 JP7781244B2 (ja) 2025-12-05

Family

ID=72744866

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022517374A Ceased JP2022548690A (ja) 2019-09-20 2020-09-18 Parg阻害剤としての4-置換インドールおよびインダゾールスルホンアミド誘導体
JP2024193094A Active JP7781244B2 (ja) 2019-09-20 2024-11-01 Parg阻害剤としての4-置換インドールおよびインダゾールスルホンアミド誘導体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022517374A Ceased JP2022548690A (ja) 2019-09-20 2020-09-18 Parg阻害剤としての4-置換インドールおよびインダゾールスルホンアミド誘導体

Country Status (12)

Country Link
US (1) US20220389003A1 (enExample)
EP (1) EP4031249A1 (enExample)
JP (2) JP2022548690A (enExample)
KR (1) KR20220066922A (enExample)
CN (1) CN114555593A (enExample)
AU (1) AU2020348489A1 (enExample)
BR (1) BR112022004624A2 (enExample)
CA (1) CA3147493A1 (enExample)
IL (1) IL291436A (enExample)
MX (1) MX2022003276A (enExample)
TW (1) TWI873187B (enExample)
WO (1) WO2021055744A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
EP4413000A1 (en) 2021-10-04 2024-08-14 FoRx Therapeutics AG N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
CA3225500A1 (en) 2021-10-04 2023-04-13 Ulrich Luecking Parg inhibitory compounds
IL314887A (en) 2022-02-14 2024-10-01 Arase Therapeutics Inc Inhibitors of parg
CN116693519A (zh) * 2022-03-04 2023-09-05 上海璎黎药业有限公司 一种含五元杂芳环结构化合物、其药物组合物及应用
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
TW202345809A (zh) * 2022-03-23 2023-12-01 美商愛德亞生物科學公司 作為parg抑制劑之經哌取代的吲唑化合物
KR20250002563A (ko) * 2022-04-28 2025-01-07 다나틀라스 파마슈티컬즈 씨오., 엘티디. 삼환식 헤테로고리 유도체, 조성물 및 이의 용도
TW202409036A (zh) * 2022-05-17 2024-03-01 美商858療法股份有限公司 Parg抑制劑
AU2023271807A1 (en) 2022-05-17 2025-01-02 858 Therapeutics, Inc. Inhibitors of parg
KR20250028378A (ko) * 2022-06-29 2025-02-28 항저우 신알엑스 테라퓨틱스 바이오메디컬 테크놀로지 컴퍼니 리미티드 5원 및 6원 융합 질소 함유 화합물, 이의 중간체, 제조 방법 및 용도
AU2023310489A1 (en) * 2022-07-19 2025-02-13 Evopoint Biosciences Co., Ltd. Sulfur-containing heteroaromatic ring compound, pharmaceutical composition thereof, and use thereof
EP4311829A1 (en) 2022-07-28 2024-01-31 Nodus Oncology Limited Substituted bicyclic heteroaryl sulfonamide derivatives for the treatment of cancer
AU2023355735A1 (en) 2022-10-03 2025-04-03 Forx Therapeutics Ag Parg inhibitory compound
AR130748A1 (es) * 2022-10-13 2025-01-15 Hanmi Pharmaceutical Co Ltd Compuesto heterobicíclico para inhibir la interacción yap-tead y composición farmacéutica que lo comprende
EP4646208A1 (en) 2023-01-06 2025-11-12 Ideaya Biosciences, Inc. Treatment of er+ breast cancer comprising homologous recombination deficiency using parg inhibitor
WO2024173234A1 (en) * 2023-02-13 2024-08-22 Arase Therapeutics Inc. Inhibitors of parg
WO2024173453A1 (en) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted imidazopyridine compounds
WO2024173530A1 (en) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted pyrazolo/imidazo pyridine compounds
WO2024173514A1 (en) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Amide and ester-substituted imidazopyridine compounds
WO2024173524A1 (en) * 2023-02-14 2024-08-22 Ideaya Biosciences, Inc. Heteroaryl-substituted benzimidazole compounds
CN121335701A (zh) 2023-04-05 2026-01-13 艾迪亚生物科学公司 用于治疗癌症的包含parg抑制剂和拓扑异构酶抑制剂的联合疗法
WO2024209035A1 (en) 2023-04-05 2024-10-10 Forx Therapeutics Ag Parg inhibitory compounds
AU2024262278A1 (en) * 2023-04-27 2025-12-18 Danatlas Pharmaceuticals Co., Ltd. Tricyclic heterocyclic derivatives, compositions and uses thereof
WO2024254990A1 (zh) * 2023-06-16 2024-12-19 上海璎黎药业有限公司 一种杂芳环结构化合物、其药物组合物及应用
WO2025046148A1 (en) 2023-09-01 2025-03-06 Forx Therapeutics Ag Novel parg inhibitors
WO2025064745A1 (en) * 2023-09-20 2025-03-27 Ideaya Biosciences, Inc. Parg inhibitor
WO2025064750A1 (en) 2023-09-20 2025-03-27 Ideaya Biosciences, Inc. Combination therapy with a parg inhibitor
WO2025072544A1 (en) * 2023-09-27 2025-04-03 Ideaya Biosciences, Inc. Sulfonamino indazole compounds as inhibitors of parg
WO2025067464A1 (zh) * 2023-09-28 2025-04-03 杭州圣域生物医药科技有限公司 杂芳基化合物、其中间体、制备方法和应用
WO2025073870A1 (en) 2023-10-03 2025-04-10 Forx Therapeutics Ag Parg inhibitory compound
CN119859145A (zh) * 2023-10-20 2025-04-22 上海璎黎药业有限公司 一种杂芳环磺酰胺结构化合物、其药物组合物及应用
WO2025087941A1 (en) 2023-10-23 2025-05-01 Universite De Geneve Parg inhibitors in combination with parp inhibitors and uses thereof
TW202523299A (zh) * 2023-10-26 2025-06-16 大陸商上海齊魯製藥研究中心有限公司 Parg抑制劑
WO2025093755A1 (en) 2023-11-01 2025-05-08 Forx Therapeutics Ag Novel parc inhibitors
WO2025098445A1 (zh) * 2023-11-07 2025-05-15 南京同诺康医药科技有限公司 Parg抑制剂及其制备方法和用途
WO2025108225A1 (zh) * 2023-11-20 2025-05-30 上海复星医药(集团)股份有限公司 作为parg抑制剂的含氮三环衍生物
TW202539682A (zh) * 2023-11-21 2025-10-16 美商858療法股份有限公司 使用parg抑制劑對癌症之治療
TW202529739A (zh) * 2023-11-22 2025-08-01 美商858療法股份有限公司 Parg之抑制劑
WO2025133396A1 (en) 2023-12-22 2025-06-26 Forx Therapeutics Ag Novel bicyclo heteroaryl parg inhibitors
WO2025133191A1 (en) * 2023-12-22 2025-06-26 Genecode Novel sulfonamides or sulfones and their use as neuroprotective and/or neurorestorative agents
WO2025229549A1 (en) * 2024-04-30 2025-11-06 Satyarx Pharma Innovations Pvt Ltd Novel heterocyclic compounds as inhibitors of parg
CN118459452B (zh) * 2024-07-10 2024-10-25 苏州国匡医药科技有限公司 一种多聚adp核糖水解酶抑制剂及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
SK285141B6 (sk) 1996-02-13 2006-07-07 Astrazeneca Uk Limited Použitie chinazolínového derivátu, chinazolínový derivát, spôsob jeho prípravy a farmaceutická kompozícia, ktorá ho obsahuje
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SK288138B6 (sk) 1999-02-10 2013-11-04 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
MXPA02011770A (es) 2000-05-31 2003-04-10 Astrazeneca Ab Derivados de indol con actividad de dano vascular.
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
US20050277627A1 (en) 2000-07-07 2005-12-15 Arnould Jean C Colchinol derivatives as vascular damaging agents
KR20030022264A (ko) 2000-07-07 2003-03-15 앤지오젠 파마슈티칼스 리미티드 신생 혈관 형성 억제제인 콜치놀 유도체
JP5865844B2 (ja) * 2011-01-07 2016-02-17 大鵬薬品工業株式会社 新規インドール、インダゾール誘導体又はその塩
MA41140A (fr) * 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) * 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
EP3697777A1 (en) * 2017-10-19 2020-08-26 eFFECTOR Therapeutics, Inc. Benzimidazole-indole inhibitors of mnk1 and mnk2
JP7500555B2 (ja) * 2018-10-25 2024-06-17 ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド ヒト免疫不全ウイルス複製の阻害剤
TW202345809A (zh) * 2022-03-23 2023-12-01 美商愛德亞生物科學公司 作為parg抑制劑之經哌取代的吲唑化合物

Similar Documents

Publication Publication Date Title
JP2025016684A5 (enExample)
JPWO2021055744A5 (enExample)
KR101985050B1 (ko) 피라진카르복사미드 화합물
US8895733B2 (en) Triazine-oxadiazoles
KR101949624B1 (ko) Tank-결합 키나제 억제제 화합물로서 유용한 아미노트리아진 유도체
IL295799A (en) Trophomyosin receptor kinase (trk) degradation compounds and methods of use
WO2022228547A1 (zh) 一种膦酰衍生物及其组合物和药学上的应用
JP7651590B2 (ja) アミノピリミジン誘導体およびアリール炭化水素受容体モジュレーターとしてのその使用
JP2025540958A (ja) 蕁麻疹の治療のための野生型c-kitキナーゼ阻害剤としてのN-フェニル-ピラゾロ[1,5-A]ピリジン-3-カルボキサミド誘導体
JP2018522929A5 (enExample)
RU2015144485A (ru) Геминально-замещенные цианоэтилпиразолопиридоны в качестве ингибиторов janus киназ
JP2024009891A (ja) T型カルシウムチャネル阻害剤
US9226916B2 (en) Pyrrolidine derivatives
JP2022081710A (ja) 関節リウマチを治療するためのt型カルシウムチャネル阻害剤の使用
EP3950059A1 (en) Use of t-type calcium channel blocker for treating pruritus
JPWO2020203609A5 (enExample)
RU2010120536A (ru) Производные пиридина и пиразина, полезные для лечения клеточных проферативных расстройств
RU2826628C1 (ru) Производные аминопиримидина и их применение в качестве модуляторов рецептора ароматических углеводородов
KR20250087568A (ko) Shp2 단백질 분해용 화합물 및 이들의 의약 용도
HK40086197A (zh) 氨基嘧啶衍生物及其作为芳烃受体调节剂的应用
JPWO2023027518A5 (enExample)